Zhejiang Haisen Pharmaceutical Third Quarter 2024 Earnings: EPS: CN¥0.28 (vs CN¥0.25 in 3Q 2023)

Simply Wall St · 10/18 22:39

Zhejiang Haisen Pharmaceutical (SZSE:001367) Third Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥109.4m (up 22% from 3Q 2023).
  • Net income: CN¥28.9m (up 11% from 3Q 2023).
  • Profit margin: 26% (down from 29% in 3Q 2023). The decrease in margin was driven by higher expenses.
  • EPS: CN¥0.28 (up from CN¥0.25 in 3Q 2023).
earnings-and-revenue-history
SZSE:001367 Earnings and Revenue History October 18th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Zhejiang Haisen Pharmaceutical shares are up 9.6% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Zhejiang Haisen Pharmaceutical that you should be aware of.